Stago Group News

FDA grants de novo for the HemoSonics’ Quantra System

March 13, 2019 : Stago is proud to announce that HemoSonics, a Stago Group company, has been granted de novo marketing authorization by the FDA for its revolutionary diagnostic device Quantra Hemostasis Analyzer platform, and its initial QPlus cartridge. The system is now commercially available in the USA.

Read more

Stago Webinar available on-demand!

The Stago webinars have successfully gathered colleagues from all around the world. If you have missed the live events or are interested in reviewing it, the 30-minute recorded version is now available online 24/7.

Read more